We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
+11.46%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$247M
AUM Growth
+$48.6M
Cap. Flow
+$29.5M
Cap. Flow %
11.97%
Top 10 Hldgs %
69.44%
Holding
26
New
5
Increased
10
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.5M
2
DYN icon
Dyne Therapeutics
DYN
+$16M
3
PCVX icon
Vaxcyte
PCVX
+$10.2M
4
LENZ
LENZ Therapeutics
LENZ
+$9.31M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$6.67M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$26.2M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.95M
3
IRON icon
Disc Medicine
IRON
+$5.73M
4
MRUS
Merus
MRUS
+$4.65M
5
SLN
Silence Therapeutics
SLN
+$2.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
1
Jazz Pharmaceuticals
JAZZ
$16B
$22M 8.9%
+206,952
New +$22.5M
IRON icon
2
Disc Medicine
IRON
$2.85B
$21M 8.5%
396,115
-122,062
-24% -$5.73M
AMLX icon
3
Amylyx Pharmaceuticals
AMLX
$2.17B
$20.9M 8.47%
3,260,570
+834,134
+34% +$4.06M
PCVX icon
4
Vaxcyte
PCVX
$8.01B
$17.7M 7.17%
544,221
+311,926
+134% +$10.2M
COGT icon
5
Cogent Biosciences
COGT
$6.91B
$16.5M 6.69%
2,297,524
+817,504
+55% +$4.53M
CELC icon
6
Celcuity
CELC
$4.01B
$15.8M 6.41%
1,185,520
+91,843
+8% +$1M
CGON icon
7
CG Oncology
CGON
$6.48B
$15.3M 6.18%
586,647
+8,951
+2% +$216K
XENE icon
8
Xenon Pharmaceuticals
XENE
$6.36B
$14.7M 5.94%
468,364
+54,653
+13% +$1.78M
DYN icon
9
Dyne Therapeutics
DYN
$4.24B
$13.9M 5.62%
+1,455,429
New +$16M
MLTX icon
10
MoonLake Immunotherapeutics
MLTX
$1.66B
$13.7M 5.56%
290,784
-53,065
-15% -$2.16M
MRUS
11
DELISTED
Merus
MRUS
$11.8M 4.78%
224,260
-98,951
-31% -$4.65M
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$10.4M 4.22%
793,327
+344,635
+77% +$4.37M
LENZ
13
LENZ Therapeutics
LENZ
$179M
$10M 4.07%
+342,312
New +$9.31M
NBIX icon
14
Neurocrine Biosciences
NBIX
$17.7B
$7.31M 2.96%
+58,181
New +$6.67M
OCUL icon
15
Ocular Therapeutix
OCUL
$1.89B
$6.76M 2.74%
728,576
+130,385
+22% +$1.02M
ASND icon
16
Ascendis Pharma A/S
ASND
$16.6B
$6.59M 2.67%
38,191
-161,073
-81% -$26.2M
ARGX icon
17
argenx
ARGX
$55.6B
$5.67M 2.3%
10,285
-3,577
-26% -$2.08M
ABVX
18
Abivax
ABVX
$11.2B
$4.76M 1.93%
622,479
+69,553
+13% +$453K
SNDX icon
19
Syndax Pharmaceuticals
SNDX
$1.82B
$4.69M 1.9%
500,551
-540,729
-52% -$5.95M
NAMS icon
20
NewAmsterdam Pharma
NAMS
$3.53B
$4M 1.62%
220,695
+104,342
+90% +$1.9M
CTNM
21
Contineum Therapeutics
CTNM
$518M
$1.27M 0.51%
319,348
-241,631
-43% -$1.05M
REPL icon
22
Replimune Group
REPL
$724M
$1.2M 0.49%
+128,917
New +$1.12M
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$710K 0.29%
62,793
-192,267
-75% -$2.35M
SLN
24
Silence Therapeutics
SLN
$570M
$201K 0.08%
34,737
-697,726
-95% -$2.99M
CRNX icon
25
Crinetics Pharmaceuticals
CRNX
$8.87B
– –
-59,017
Closed -$1.98M
1
2

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $553M AUM 26.47% 1-Year Est. Return

Saturn V Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Saturn V Capital Management held 26 positions worth $247M, up 25% from $198M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Saturn V Capital Management deployed $29.5M of net new capital in Q2 2025, opening 5 new positions and adding to 10 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 206,952 shares worth $22M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $26.2M trimmed.

  • Saturn V Capital Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 206,952 shares worth $22M.
  • Saturn V Capital Management added most to Vaxcyte in Q2 2025, an estimated $10.2M increase.
  • Saturn V Capital Management's biggest Q2 2025 reduction was Ascendis Pharma A/S, cutting an estimated $26.2M.
  • Saturn V Capital Management fully exited Crinetics Pharmaceuticals in Q2 2025, selling an estimated $1.98M.
  • Saturn V Capital Management's ten largest holdings make up 69% of its $247M portfolio in Q2 2025.
  • Saturn V Capital Management opened 5 new positions and closed 2 in Q2 2025.
  • Saturn V Capital Management's portfolio value rose 25% quarter-over-quarter to $247M.

Based on Saturn V Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.